biogen

Welcome to the 'biogen' tag page at Technorati. This page features content from the farthest reaches of the Blogosphere that authors have "tagged" with 'biogen'.

Latest blogosphere posts tagged “biogen”

• Pharmalot… Pharmalittle… The Weekend Nears

  
  Pharmalot — Authority: 587
  Good morning again and nice to see you. A busy day is expected and so we are studying our to-do list as another deadline looms. Meanwhile, we are also looking ahead to the weekend. Our leaves are finally gone, which means there will be more time to cavort with the short and not-so-short people. And we look forward to ...
  1 day ago

• Biogen Fattens Offer to Buy Facet Biotech

  
  Xconomy — Authority: 668
  Life Sciences , deals , buyouts Ryan McBride wrote: Cambridge, MA-based Biogen Idec reports today that it’s upping its bid to buy Facet Biotech by 21 percent, after the smaller firm’s board rejected Biogen’s earlier buyout offer in October . Biogen (NASDAQ: BIIB ) said it would pay $17.50 per ...
  1 day ago

• (BMRN) BioMarin Pharmaceutical Earns Orphan Status From FDA

  
  Stock Blog Hub — Authority: 460
  Recently, BioMarin Pharmaceutical Inc. ( BMRN ) announced that the U.S. Food and Drug Administration (FDA) granted orphan drug status to its candidate 3,4-diaminopyridine amifampridine phosphate (3,4-DAP), for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). As a reminder, BioMarin acquired the privately ...
  3 days ago

• A Sapphire Energy Co-Founder Sees Solutions in Algae for Drugs as Well as Biofuels

  
  Xconomy — Authority: 668
  Algae-based technologies , Drug Development , people Denise Gellene wrote: The potential of algae as a clean energy source has been generating a lot of entrepreneurial excitement in San Diego. At last count, 10 local companies are busy working on technologies focused on transforming ordinary pond scum ...
  3 days ago

• Panel of multiple sclerosis experts provides best practice treatment recommendations for Tysabri

  
  Science Blog - Science news straight from the source — Authority: 641
  Best-practice recommendations for the selection and management of patients with multiple sclerosis (MS) who may benefit from, or are receiving treatment with TYSABRI® (natalizumab) were published today in a supplement to the medical journal Multiple Sclerosis . The panel provided recommendations focusing on ...
  5 days ago

• Hyper-Analytical “Insanity” Cripples Drug R&D, Says Alnylam CEO John Maraganore

  
  Xconomy — Authority: 668
  Biotech , people , management Luke Timmerman wrote: There’s one thing drug makers love to use to figure out which drugs to invest in: spreadsheets. Not Alnylam Pharmaceuticals, though. Estimates of future cash flows and other financial analysis tools are one of the big reasons why drugmakers spend so ...
  5 days ago

• Ironwood Pharma Eyes $172.5M IPO, Biogen CEO Pay Under Fire, & More Boston Life Sciences News

  
  Xconomy — Authority: 668
  Life Sciences , deals , Multiple Sclerosis Ryan McBride wrote: Xconomy’s life sciences coverage this past week featured a mix of exclusive feature stories—such as Luke’s analysis of the PML side effect from Biogen Idec’s natalizumab (Tysabri)—and breaking news stories like Ironwood ...
  1 week ago

• Receptos, Led By Biogen Idec Vets and Scripps Stars, Snags $25M For Drug Discovery Engine

  
  Xconomy — Authority: 668
  Biotech , VC , startups Luke Timmerman wrote: Receptos , a San Diego-based biotech startup formed by a number of Biogen Idec veterans, has nailed down $25 million in venture capital to develop a vivid new way to look at certain protein structures on cells that it hopes will ultimately take a lot of ...
  1 week ago

• ImmunoGen Signs 2nd Licensing Deal with Amgen

  
  OneMedPlace — Authority: 465
  ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million. The deal gives biotechnology company Amgen the right to use ImmunoGen’s maytansinoid targeted antibody payload (TAP) technology to create cancer-fighting therapies to an undisclosed target. In addition to the ...
  1 week ago

• (BIIB) Biogen’s Rituxan Label Expansion Delayed

  
  Stock Blog Hub — Authority: 460
  Biogen Idec ( BIIB ) and Genentech, Inc., a wholly-owned member of the Roche Group (RHHBY.PK), announced that they have received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for Rituxan. The companies were seeking approval for the use of Rituxan (rituximab) plus fludarabine and ...
  2 weeks ago

• Biogen Idec Accused Again of Excessive CEO Pay, Lousy Performance, By Big Shareholder

  
  Xconomy — Authority: 668
  Biotech , Drugs , Multiple Sclerosis Luke Timmerman wrote: After a bitter standoff earlier this year with billionaire investor Carl Icahn over alleged mismanagement , Cambridge, MA-based Biogen Idec now faces another sharp attack from a major shareholder. New York-based HealthCor Management, a hedge ...
  2 weeks ago

• Tysabri, the MS Drug Haunted by Deadly Side Effect, Doesn’t Look So Deadly Anymore

  
  Xconomy — Authority: 668
  Biotech , Multiple Sclerosis , Drugs Luke Timmerman wrote: Few doctors knew much about a rare brain infection called PML back in 2005, when two patients on a hot new multiple sclerosis drug from Biogen Idec and Elan died from the side effect. The infection, at the time, was generally considered a ...
  2 weeks ago

• (ALNY) Alnylam Pharmaceuticals Posts Wider Loss

  
  Stock Blog Hub — Authority: 460
  Alnylam Pharmaceuticals Inc. ( ALNY ) reported a third-quarter loss of 22 cents per share, below the Zacks Consensus Estimate of 24 cents but wider than the year-ago loss of 7 cents. The higher loss in the quarter is attributable to higher stock based compensation and legal expenses. Revenues for the quarter came ...
  2 weeks ago

• (RX) Big Pharma and Biotech – Industry Outlook

  
  Stock Blog Hub — Authority: 460
  The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent ...
  3 weeks ago

• Pharmalot… Pharmalittle… Good Morning

  
  Pharmalot — Authority: 587
  Welcome to the working week. Hope your weekend was relaxing. Now, of course, it’s time to turn our attention to meetings, deadlines and projects, as always. So as you reach for a cup of stimulation, here are a few items to help you get oriented. Have a good day, everyone… Ranbaxy Says FDA Issues Will Take Time ...
  3 weeks ago

• Vertex and Ironwood Drugs Fare Well in Clinical Trials, Pulmatrix Breathes in $30.2M, IRobot Launches Healthcare Unit, & More Boston-Area Life Sciences News

  
  Xconomy — Authority: 668
  Roundup , Life Sciences , VC Rebecca Zacks wrote: A number of New England’s life sciences companies had good news to report this week. —Cambridge, MA-based Vertex Pharmaceuticals (NASDAQ: VRTX ) reported results from clinical trials that indicate its experimental hepatitis C drug, telaprevir, could ...
  4 weeks ago

• (MDCO) Medicines Co. Misses Forecasts & Cuts Projections

  
  Stock Blog Hub — Authority: 460
  Medicines Co. ’s ( MDCO ) third-quarter loss per share of 6 cents missed the Zacks Consensus Estimate of a loss of 5 cents. Revenues increased 12% to $98.8 million from $88.13 million in the year ago period driven by strong sales of Angiomax (bivalirudin). Angiomax, the lead product of the company that was acquired ...
  4 weeks ago

• Tysabri Is Now Linked To Four Deaths: EMEA

  
  Pharmalot — Authority: 587
  The patients died of a deadly brain infection known as PML, and 24 cases of the disease have been diagnosed since Tysabri was reintroduced to the market in 2006, the European Medicines Agency told Bloomberg News . The FDA confirmed the number of PML cases as 24, but declined further comment. “We’re not ...
  5 weeks ago

• (GSK) GlaxoSmithKline Earns FDA Approval for Arzerra, a Chronic Lymphocytic Leukemia Drug

  
  Stock Blog Hub — Authority: 460
  GlaxoSmithKline ( GSK ) and Denmark-based Genmab received some good news with the US Food and Drug Administration’s (FDA) approval for Arzerra (ofatumumab), a monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow. Arzerra is approved for ...
  5 weeks ago

• Virdante Pharma Lands $30M in A Round to Combat Inflammation

  
  Xconomy — Authority: 668
  deals , Life Sciences , Antibodies Ryan McBride wrote: Virdante Pharmaceuticals is expanding development of its anti-inflammatory drugs with a second closing of what is now a $30 million Series A round of venture capital, the company’s CEO, John Ripple, said. The Cambridge, MA-based biotech startup ...
  5 weeks ago

Comments about biogen